DE69328430D1 - Zielgerichte liposome zur blut-hirne schranke - Google Patents

Zielgerichte liposome zur blut-hirne schranke

Info

Publication number
DE69328430D1
DE69328430D1 DE69328430T DE69328430T DE69328430D1 DE 69328430 D1 DE69328430 D1 DE 69328430D1 DE 69328430 T DE69328430 T DE 69328430T DE 69328430 T DE69328430 T DE 69328430T DE 69328430 D1 DE69328430 D1 DE 69328430D1
Authority
DE
Germany
Prior art keywords
receptors
blood brain
targeted
targeted liposome
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328430T
Other languages
English (en)
Other versions
DE69328430T2 (de
Inventor
Michael J Micklus
Nigel H Greig
Stanley I Rapoport
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, National Institutes of Health NIH filed Critical US Department of Health and Human Services
Publication of DE69328430D1 publication Critical patent/DE69328430D1/de
Application granted granted Critical
Publication of DE69328430T2 publication Critical patent/DE69328430T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
DE69328430T 1992-07-27 1993-07-23 Zielgerichte liposome zur blut-hirne schranke Expired - Fee Related DE69328430T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92119992A 1992-07-27 1992-07-27
PCT/US1993/006942 WO1994002178A1 (en) 1992-07-27 1993-07-23 Targeting of liposomes to the blood-brain barrier

Publications (2)

Publication Number Publication Date
DE69328430D1 true DE69328430D1 (de) 2000-05-25
DE69328430T2 DE69328430T2 (de) 2001-01-25

Family

ID=25445079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328430T Expired - Fee Related DE69328430T2 (de) 1992-07-27 1993-07-23 Zielgerichte liposome zur blut-hirne schranke

Country Status (8)

Country Link
US (1) US20020025313A1 (de)
EP (1) EP0652775B1 (de)
JP (1) JPH07509250A (de)
AT (1) ATE191853T1 (de)
AU (1) AU677216B2 (de)
CA (1) CA2141216A1 (de)
DE (1) DE69328430T2 (de)
WO (1) WO1994002178A1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
WO1996026745A1 (en) * 1995-02-28 1996-09-06 Nature Technology Corporation Biosynthetic virus vectors for gene therapy
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
AU6443298A (en) 1997-02-28 1998-09-18 Nature Technology Corporation Self-assembling genes, vectors and uses thereof
AU8269898A (en) * 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2481020A1 (en) * 2001-09-28 2003-04-03 Saoirse Corporation Localized non-invasive biological modulation system
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
AU2003222185A1 (en) * 2002-04-01 2003-10-20 Utah Ventures Ii, L.P. Tissue-specific endothelial membrane proteins
PL210412B1 (pl) * 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7592143B2 (en) * 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
EP2283831A3 (de) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarker zur Vorauswahl von Patienten für die Anti-IGF1R-Therapie
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US9943481B2 (en) 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
CN103396485B (zh) 2005-12-15 2016-08-10 健泰科生物技术公司 靶向多聚泛蛋白的方法和组合物
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
KR20190003862A (ko) 2006-07-14 2019-01-09 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
BRPI0717794B8 (pt) 2006-10-12 2021-05-25 Bellus Health International Ltd composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2529174T3 (es) 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
TWI516500B (zh) 2007-06-12 2016-01-11 Ａｃ免疫公司 抗β類澱粉蛋白單株抗體
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
ES2609918T3 (es) 2007-10-05 2017-04-25 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP3187508A1 (de) 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
SG10201605250SA (en) 2008-10-14 2016-08-30 Genentech Inc Immunoglobulin variants and uses thereof
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
CN102264759B (zh) 2008-12-23 2016-05-11 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体
WO2011005098A1 (en) 2009-07-10 2011-01-13 Abbott Healthcare Products B.V. Peptide ligands for targeting to the blood-brain barrier
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
CA2778483A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Modulation of axon degeneration
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2509953B1 (de) 2009-12-11 2016-03-30 Genecode AS Verfahren für das überleben von nervenzellen mit ligandenmimetika der gdnf-familie oder aktivatoren des ret-signalweges
DK2516465T3 (en) 2009-12-23 2016-06-06 Hoffmann La Roche ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CN104777301B (zh) 2010-05-10 2018-04-20 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
EP2603233A1 (de) 2010-08-12 2013-06-19 AC Immune S.A. Manipulation von impfstoffen
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
CA2812865C (en) 2010-10-07 2021-01-26 Ac Immune S.A. Phosphospecific antibodies recognising tau
AU2011322553B2 (en) 2010-10-26 2015-07-02 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
PE20140238A1 (es) 2010-11-10 2014-03-07 Genentech Inc Metodos y composiciones para inmunoterapia para enfermedad neural
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
JP2014506922A (ja) 2011-03-01 2014-03-20 ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ 難水溶性物質の高度なアクティブリポソームローディング
JP6144673B2 (ja) 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
EP2739304A4 (de) * 2011-08-04 2015-06-03 Univ Ramot Partikel zur behandlung von neurodegenerativen erkrankungen
RU2639537C2 (ru) 2011-10-07 2017-12-21 Ац Иммуне С.А. Фосфоспецифичные антитела, распознающие тау
WO2013056054A2 (en) 2011-10-14 2013-04-18 Genentech, Inc Peptide inhibitors of bace1
CN103930568A (zh) 2011-11-10 2014-07-16 霍夫曼-拉罗奇有限公司 用于治疗、诊断和监测阿尔茨海默病的方法
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
BR112014028838A2 (pt) 2012-05-21 2020-05-12 Genentech Inc Usos de um anticorpo, método para fazer um anticorpo e anticorpos
WO2013174780A1 (en) 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
CA2885908A1 (en) 2012-09-27 2014-04-03 F. Hoffmann-La Roche Ag Substituted sulfonamide compounds
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
CN105164114B (zh) 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
SG11201509027WA (en) 2013-05-01 2015-12-30 Hoffmann La Roche Biheteroaryl compounds and uses thereof
PL3594240T3 (pl) 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
EP3038600B1 (de) 2013-08-27 2020-06-03 Northeastern University System zur freisetzung von wirkstoffen in nanopartikelform und verfahren zur behandlung von krebs und neurotraumata
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
LT3055302T (lt) 2013-10-11 2019-03-12 F. Hoffmann-La Roche Ag Pakeistieji heterocikliniai sulfonamidiniai junginiai, tinkami naudoti kaip trpa1 moduliatoriai
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EP3087193A4 (de) * 2013-12-27 2017-08-09 Teloregen, Inc. Zusammensetzungen und verfahren zur bereitstellung von aktiver telomerase an zellen in vivo
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
JP6894239B2 (ja) 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP3221361B1 (de) 2014-11-19 2021-04-21 Genentech, Inc. Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221364B1 (de) 2014-11-19 2020-12-16 Genentech, Inc. Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
PL3221349T3 (pl) 2014-11-19 2021-05-17 Axon Neuroscience Se Humanizowane przeciwciała tau w chorobie Alzheimera
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CN107430127B (zh) 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
JP6942633B2 (ja) 2015-01-30 2021-09-29 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
NZ737536A (en) 2015-05-22 2019-04-26 Genentech Inc Substituted benzamides and methods of use thereof
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
EP3344806A4 (de) 2015-09-04 2019-03-20 OBI Pharma, Inc. Glycanarrays und verfahren zur verwendung
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
JP6975515B2 (ja) 2016-07-20 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
EP3487853B1 (de) 2016-07-20 2022-06-08 F. Hoffmann-La Roche AG Bicyclische prolinverbindungen
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CN109803964A (zh) 2016-08-12 2019-05-24 豪夫迈·罗氏有限公司 磺酰基吡啶基trp抑制剂
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
WO2018096159A1 (en) 2016-11-28 2018-05-31 F. Hoffmann-La Roche Ag Oxadiazolones as transient receptor potential channel inhibitors
CN110023313B (zh) 2016-12-02 2022-10-25 豪夫迈·罗氏有限公司 二环酰胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7178357B2 (ja) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN108939089B (zh) * 2017-05-17 2021-11-02 复旦大学 群体感应多肽及其在制备肿瘤靶向诊治递药系统中的用途
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CA3067944C (en) 2017-07-14 2023-03-14 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
MA50356A (fr) 2017-10-11 2021-04-21 Hoffmann La Roche Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
CA3078676A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
CN111278809A (zh) 2017-10-31 2020-06-12 豪夫迈·罗氏有限公司 二环砜类和亚砜类、以及其使用方法
TWI805653B (zh) 2017-11-30 2023-06-21 韓商韓美藥品股份有限公司 4-胺基-n-(1-((3-氯-2-氟苯基)胺基)-6-甲基異喹啉-5-基)噻吩并[3,2-d]嘧啶-7-甲醯胺之鹽及其結晶型
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
AR114585A1 (es) 2018-02-20 2020-09-23 Hoffmann La Roche Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
KR20200144551A (ko) 2018-03-28 2020-12-29 악손 뉴로사이언스 에스이 알츠하이머병을 검출하고 치료하는 항체-기반 방법
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
EP3898667A2 (de) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modifizierter antikörper fcs und verwendungsverfahren
AR119673A1 (es) 2019-01-11 2022-01-05 Hoffmann La Roche Compuestos bicíclicos de cetona y métodos para utilizarlos
EP3946269A4 (de) * 2019-03-27 2023-05-03 University of Georgia Research Foundation, Inc. Verfahren zur herstellung gezielter vesikel und so hergestellte zusammensetzungen
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
MX2022005775A (es) 2019-11-13 2022-06-09 Genentech Inc Compuestos terapeuticos y metodos de uso.
WO2021110995A1 (en) 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
AR123254A1 (es) 2020-08-14 2022-11-16 Ac Immune Sa Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
AU2021353532A1 (en) 2020-10-02 2023-04-13 F. Hoffmann-La Roche Ag Process for the preparation of biheteroaryl compounds and crystal forms thereof
EP4229082A1 (de) 2020-10-16 2023-08-23 AC Immune SA Alpha-synuclein bindende antikörper zur therapie und diagnose
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
WO2023028077A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. Sodium channel inhibitors and methods of designing same
US20230202984A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
WO2023097194A2 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic compounds and methods of use
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010819A1 (en) * 1991-11-26 1993-06-10 Alkermes, Inc. Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2025907A1 (en) * 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
WO1991019501A1 (en) * 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane

Also Published As

Publication number Publication date
AU4687593A (en) 1994-02-14
AU677216B2 (en) 1997-04-17
EP0652775A1 (de) 1995-05-17
ATE191853T1 (de) 2000-05-15
EP0652775B1 (de) 2000-04-19
DE69328430T2 (de) 2001-01-25
CA2141216A1 (en) 1994-02-03
WO1994002178A1 (en) 1994-02-03
US20020025313A1 (en) 2002-02-28
JPH07509250A (ja) 1995-10-12

Similar Documents

Publication Publication Date Title
DE69328430D1 (de) Zielgerichte liposome zur blut-hirne schranke
RU2764031C2 (ru) Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
Lawasut et al. New proteasome inhibitors in myeloma
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
RU2628089C2 (ru) Комбинированная терапия иммуноцитокинами
WO2007097934A3 (en) Methods and compositions for using erythrocytes as carriers for delivery of drugs
Cusack Jr et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
ATE207738T1 (de) Verfahren zur baladung von lipidvesikeln
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EA199700197A1 (ru) Стабильные белково-фосфолипидные составы и способы их получения
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
ZA200200789B (en) Multiple cytokine-antibody complexes.
BRPI0406605B8 (pt) conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
MXPA04003569A (es) Mezclas bifasicas de glp-1 e insulina.
CN105294859A (zh) 脂蛋白复合物及其制备和用途
GB9814527D0 (en) Delivery system
Spitzer et al. A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
JP4836384B2 (ja) 癌療法における使用のための修飾サイトカイン類
ATE322255T1 (de) Polyamid-oligomere
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
US20040071691A1 (en) Pharmaceutical formulation
WO2002058589A3 (en) Agents and methods for promoting bone growth
Chène p53 as a drug target in cancer therapy

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: EFFERT UND KOLLEGEN, 12487 BERLIN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: WABLAT-LANGE-KARTHAUS, 14129 BERLIN

8339 Ceased/non-payment of the annual fee